Literature DB >> 19596971

Controversies in the management of ovarian cancer--pros and cons for lymph node dissection in ovarian cancer.

Oumar Camara1, Jalid Sehouli.   

Abstract

Up-front maximal surgical effort towards cytoreduction with the primary goal of maximum tumour resection is one of the cornerstones in the multimodal management of ovarian cancer. Despite the prognostic relevance of lymph node metastasis, there is a great debate about the role of pelvic and para-aortic lymph node dissection. In early-stage ovarian cancer, lymph node dissection is required to make an accurate clinical staging according to the FIGO classification and to select adequate adjuvant therapy. The effect of lymph node dissection on progression-free survival and overall survival in patients with advanced ovarian cancer is still unknown. There has only been one randomized trial which favoured systematic lymph node dissection instead of lymph node sampling due to significantly better progression-free survival, but there was no difference in overall survival. Patients with postoperative tumour residuals are unlikely to benefit from this procedure. The German AGO has now initiated the first study in advanced ovarian cancer (LION) which compares the value of systematic lymph node dissection with no lymph node resection in patients without any visible tumour residuals. Until these data are in fact available, patients with advanced ovarian cancer should be informed in detail about the pros and cons of systematic lymph node dissection.

Entities:  

Mesh:

Year:  2009        PMID: 19596971

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Asian society of gynecologic oncology workshop 2010.

Authors:  Dong Hoon Suh; Jae Weon Kim; Mohamad Farid Aziz; Uma K Devi; Hextan Y S Ngan; Joo-Hyun Nam; Seung Cheol Kim; Tomoyasu Kato; Hee Sug Ryu; Shingo Fujii; Yoon Soon Lee; Jong Hyeok Kim; Tae-Joong Kim; Young Tae Kim; Kung-Liahng Wang; Taek Sang Lee; Kimio Ushijima; Sang-Goo Shin; Yin Nin Chia; Sarikapan Wilailak; Sang Yoon Park; Hidetaka Katabuchi; Toshiharu Kamura; Soon-Beom Kang
Journal:  J Gynecol Oncol       Date:  2010-09-28       Impact factor: 4.401

2.  Prognostic value of lymph node ratio in stage IIIC epithelial ovarian cancer with node-positive in a SEER population-based study.

Authors:  Juan Zhou; Zhen-Yu He; Feng-Yan Li; Jia-Yuan Sun; Huan-Xin Lin; San-Gang Wu; Qiong-Hua Chen
Journal:  Oncotarget       Date:  2016-02-16

3.  Delineation of retroperitoneal metastatic lymph nodes in ovarian cancer with near-infrared fluorescence imaging.

Authors:  Tao Pu; Liqin Xiong; Qiyu Liu; Minxing Zhang; Qingqing Cai; Haiou Liu; Anil K Sood; Guiling Li; Yu Kang; Congjian Xu
Journal:  Oncol Lett       Date:  2017-07-05       Impact factor: 2.967

4.  Early ovarian cancer surgery with indocyanine-green-guided targeted compartmental lymphadenectomy (TCL, pelvic part).

Authors:  Rainer Kimmig; Paul Buderath; Peter Rusch; Pawel Mach; Bahriye Aktas
Journal:  J Gynecol Oncol       Date:  2017-06-13       Impact factor: 4.401

5.  Surgical treatment of early ovarian cancer with compartmental resection of regional lymphatic network and indocyanine-green-guided targeted compartmental lymphadenectomy (TCL, paraaortic part).

Authors:  Rainer Kimmig; Paul Buderath; Pawel Mach; Peter Rusch; Bahriye Aktas
Journal:  J Gynecol Oncol       Date:  2017-03-21       Impact factor: 4.401

6.  CT Scan in the Prediction of Lymph Node Involvement in Ovarian Cancer - a Retrospective Analysis of a Tertiary Gyneco-Oncological Unit.

Authors:  Peter Widschwendter; Alexandra Blersch; Thomas W P Friedl; Wolfgang Janni; Christopher Kloth; Amelie de Gregorio; Niko de Gregorio
Journal:  Geburtshilfe Frauenheilkd       Date:  2020-03-24       Impact factor: 2.915

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.